Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roche

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

Investors Business Daily

Vet's lawsuit blaming antimalarial drug for psychosis tossed

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

The Independent UK

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.

Investors Business Daily

Disappointment after potential Alzheimer’s drug fails Roche trial

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

The Guardian - UK

Biogen Stock Leaps, Eli Lilly Gains As Roche Alzheimer's Drug Trial Falls Short

"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer’s dataset to the field," Roche said.

The Street

Blow for people with Alzheimer's as 'promising' new Roche gantenerumab jab fails

The drug had held promise in earlier trials

Wales Online

Read news from The Economist, FT, and more,
with one subscription

Alzheimer’s jab failed to meet goal on reducing memory decline, company says

Previous data had shown that gantenerumab reduced levels of brain amyloid plaque.

The Independent UK

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

Recursion Pharmaceuticals Puts Strength on Full Display

The drug developer's latest capital raise, a $150 million private placement, comes during a difficult market environment.

The Street

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity

Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.

Investors Business Daily

Three Stocks That Can Thrive in a Recession: Morningstar

Recession-resistant companies are usually financially healthy and very profitable, Morningstar said.

The Street

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation

Dow Jones Pares Early Losses; Warren Buffett's Fund Makes Low-Volatility List; Meme Shares Plunge; Bitcoin Flashes

Major indexes gave up Wednesday's gains on strong job data. The Dow Jones Industrial Average pared back some of today's early losses of 2% and was off 1.2% at noon ET. The Nasdaq also traded slightly above morning's lows, down 2.5%, while the S&P 500 moderated its decline to 1.7%.…

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

The Street

Regeneron's Eylea Win Leaves an Elephant in the Room

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

Financial Times

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Benzinga

Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21

CNBC

Investors Business Daily

Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug

Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.

The Street

Value Stocks Crushing Growth and the Trend May Continue

The Russell 1000 Value index has slumped 12% so far this year, while Russell 1000 Growth has dropped 25%.

The Street

Clorox Makes Morningstar List of Stocks to Beat Volatility

Competitive advantages and good management are keys to stocks that will cope during tumultuous markets.

Investors Business Daily

Stock Market Falls On Recession Fears; Energy, Tech Losses Mount

Energy, consumer discretionary and tech stocks lead declines in stock market.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.